Coronavirus channel feed

Fau­ci push­es back on pan­dem­ic crit­i­cisms be­fore di­vid­ed House pan­el

11 months ago
Pharma
FDA+

NIH of­fi­cials used per­son­al emails, tweaked words to skirt FOIA search­es dur­ing pan­dem­ic, law­mak­ers find

11 months ago
Pharma
FDA+

Mod­er­na scores Eu­ro­pean vic­to­ry over Pfiz­er and BioN­Tech in mR­NA patent bat­tle

11 months ago
Pharma

As­traZeneca's suc­ces­sor to Covid block­buster Evusheld suc­ceeds in Phase 3 tri­al

11 months ago
R&D

Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

12 months ago
R&D

Sanofi grabs a share of No­vavax's Covid vac­cine for $500M, eye­ing com­mer­cial­iza­tion, flu com­bi­na­tion

Last year
Deals
Pharma

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Last year
R&D
Pharma

Paxlovid didn’t short­en Covid symp­toms in vac­ci­nat­ed adults, full tri­al re­sults con­firm

Last year
Pharma
FDA+

NIH sends BioN­Tech 'no­tice of de­fault' over Covid vac­cine roy­al­ties

Last year
Pharma

Mod­er­na turns the spot­light on long Covid with new ini­tia­tives

Last year
Pharma
Marketing

Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Last year
R&D
Pharma

House Re­pub­li­cans take is­sue with DO­J's han­dling of Mod­er­na's Covid vac­cine patents

Last year

No­vavax an­nounces an­oth­er round of lay­offs, lets go 12% of em­ploy­ees

Last year
People

Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

Last year
R&D

Pfiz­er and BioN­Tech urge US patent re­view board to take on Mod­er­na's Covid patents

Last year
Pharma
Law

In­vivyd re­quests emer­gency use au­tho­riza­tion for Covid-19 pre­ven­tive an­ti­body among im­muno­com­pro­mised

Last year
FDA+

Up­dat­ed: Eu­ro­pean Com­mis­sion au­tho­rizes No­vavax's up­dat­ed Covid vac­cine

Last year
Pharma
FDA+

Like Mod­er­na, pan­dem­ic peers Pfiz­er and BioN­Tech head to PhI­II with Covid/flu com­bo jab

Last year
R&D
Pharma

Pfiz­er sets Paxlovid price at $1,390 for five-day course

Last year
Pharma

BioN­Tech ex­pects up to $950M in Covid vac­cine write-offs af­ter Pfiz­er low­ers ex­pec­ta­tions

Last year
Financing

Mod­er­na's new Covid-19 vac­cine analy­sis 'giv­ing weight' to an­nu­al boost­ing in­ter­val, com­pa­ny says

Last year
Pharma

Mod­er­na eyes PhI­II start for com­bo mR­NA jab tar­get­ing Covid and flu af­ter PhI/II suc­cess

Last year
R&D

FDA clears No­vavax’s fall boost­er for Covid-19, weeks af­ter mR­NA vac­cine boost­ers 

Last year
Pharma
FDA+

Ex-Warp Speed vac­cine leader nabs NextGen funds for Mod­eX Ther­a­peu­tics’ Covid-19 an­ti­bod­ies

Last year
Deals
First page Previous page 12345 Next page Last page
A service from the Financial Times